Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 3/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.43 |
| ▸ | CCR4 | P51679 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2972278 | 0.90 | SIGMAR1 (0.55) | BCHESIGMAR1OPRL1 | |
| SCHEMBL2979356 | 0.85 | OPRM1 (0.52) | DRD4HRH3SLC6A4CXCR3 | |
| SCHEMBL2979865 | 0.84 | HTR1A (0.45) | SLC6A4HTR1ASIGMAR1 | |
| SCHEMBL2982100 | 0.83 | CCR3 (0.42) | DRD4HRH3SIGMAR1 | |
| SCHEMBL2981930 | 0.82 | DRD3 (0.46) | BCHESIGMAR1 | |
| SCHEMBL2982820 | 0.82 | HTR1A (0.46) | DRD4SLC6A4HTR1ASIGMAR1OPRL1 | |
| SCHEMBL2980435 | 0.79 | KCNA3 (0.51) | SIGMAR1 | |
| SCHEMBL2982162 | 0.79 | POLB (0.52) | BCHE | |
| SCHEMBL2975028 | 0.77 | ARG1 (0.44) | SLC6A4HTR1ASIGMAR1 | |
| SCHEMBL2970167 | 0.76 | SIGMAR1 (0.49) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1720550-B1 | DERIVATIVES OF PIPERIDINYLALKYLCARBAMATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FAAH ENZYME INHIBITORS | SANOFI AVENTIS (FR) | 2009-04-15 | — | — | EP | claimed |
| US-20100279998-A1 | PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS | SANOFI-AVENTIS (FR) | 2010-11-04 | — | — | US | disclosed |
| US-7781590-B2 | Piperidinylalkylcarbamate derivatives, methods for their preparation and the therapeutic use thereof as fatty acid amido hydrolase enzyme inhibitors | SANOFI-AVENTIS (FR) | 2010-08-24 | — | — | US | disclosed |
| US-20070021403-A1 | PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS | SANOFI-AVENTIS (FR) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279998-A1 | PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS | FAAH, FAAH2, CNR2 | DRD4 2463/4885HRH3 63/4885SLC6A4 1718/4885 |
| US-20070021403-A1 | PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS | FAAH, FAAH2, CNR2 | DRD4 1900/4885HRH3 65/4885SLC6A4 1489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.